Novartis Opens Pharmaceutical Plant In Singapore, Biotech Plant to Come
Novartis (Basel, Switzerland) officially opened a new pharmaceutical manufacturing site in Tuas, Singapore on October 29, 2007, adding capacity to its global production network to meet business growth and support new product launches in the US and Japanese markets.
Novartis (Basel, Switzerland) officially opened a new pharmaceutical manufacturing site in Tuas, Singapore on October 29, 2007, adding capacity to its global production network to meet business growth and support new product launches in the US and Japanese markets.
The plant will manufacture solid dosage forms of existing Novartis pharmaceutical brands, such as Diovan, and new products, like Tekturna. It is expected to be fully operational in 2009 and will employ approximately 160 employees.
Novartis also unveiled its plan to build a large-scale biotechnology plant in Singapore to support the rapid growth of its biologics sector, which now accounts for 25 percent of the Novartis product pipeline. Novartis expects to invest approximately $700 million-its largest investment to date in manufacturing capacity-in the new, state-of-the-art cell-culture facility.
Construction on the new biotech plant is expected to start in early 2008, and it will employ more than 300 people when fully operational by the end of 2012, subject to regulatory approvals. The cell-culture plant will support both clinical and commercial production of potential new products in the area of biopharmaceutical therapies, primarily monoclonal antibodies.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
